In the United States, neratinib is approved in the extended adjuvant setting in HER2+ early breast cancer irrespective of HR status, based upon the intent-to-treat principle; however, the European Medicines Agency has approved neratinib only for HR+/HER2+ patients109. Here, HR is linked to breast carcinoma.